Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - bmj, 2021 - bmj.com
Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …
[HTML][HTML] Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - The BMJ, 2021 - ncbi.nlm.nih.gov
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical
coronavirus disease 2019: randomised controlled trial - PMC Back to Top Skip to main …
coronavirus disease 2019: randomised controlled trial - PMC Back to Top Skip to main …
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - BMJ, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Objective</jats: title>< jats: p> To
determine whether tocilizumab improves clinical outcomes for patients with severe or critical …
determine whether tocilizumab improves clinical outcomes for patients with severe or critical …
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
VC Veiga, J Prats, DLC Farias, RG Rosa… - … (Clinical Research ed …, 2021 - europepmc.org
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus
disease 2019: randomised controlled trial. - Abstract - Europe PMC Sign in | Create an account …
disease 2019: randomised controlled trial. - Abstract - Europe PMC Sign in | Create an account …
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
VC VEIGA, JAGG PRATS… - BMJ-British Medical …, 2021 - observatorio.fm.usp.br
OBJECTIVE To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). DESIGN Randomised, open label …
severe or critical coronavirus disease 2019 (covid-19). DESIGN Randomised, open label …
[HTML][HTML] Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - BMJ, 2021 - covid19.sld.cu
Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - 2021 - pubmed.ncbi.nlm.nih.gov
Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - 2021 - cabidigitallibrary.org
Objective: To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design: Randomised, open label …
severe or critical coronavirus disease 2019 (covid-19). Design: Randomised, open label …
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
VC Veiga, JAGG Prats, DLC Farias… - BMJ: British Medical …, 2021 - search.proquest.com
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical
coronavirus disease 2019: randomised c Page 1 the bmj | BMJ 2021;372:n84 | doi: 10.1136/bmj.n84 …
coronavirus disease 2019: randomised c Page 1 the bmj | BMJ 2021;372:n84 | doi: 10.1136/bmj.n84 …
[HTML][HTML] Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - BMJ, 2021 - bmj.com
Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …